European Heart Journal Advance Access published online on February 12, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn021
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
1 Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland
2 Department of Social and Preventive Medicine, University Hospital Bern, Bern, Switzerland
3 Division of Cardiology, University Hospital Zurich, Zurich, Switzerland
Received 29 June 2007; revised 21 December 2007; accepted 10 January 2008.
* Corresponding author. Tel: +41 31 632 44 97, Fax: +41 31 632 47 70, Email: stephan.windecker{at}insel.ch
Aims: Percutaneous coronary intervention (PCI) in diabetic patients is associated with an increased risk of restenosis and major adverse cardiac events (MACE). We assessed the impact of diabetes on long-term outcome after PCI with sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents.
Methods and results: In the SIRTAX trial, 1012 patients were randomized to treatment with SES (n = 503) or PES (n = 509). A stratified analysis of outcomes was performed according to the presence or absence of diabetes. Baseline characteristics were well balanced between SES and PES in patients with (N = 201) and without diabetes (N = 811). Clinical outcome was worse in diabetic compared with non-diabetic patients regarding death (9.0% vs. 4.1%, P = 0.004) and MACE (defined as cardiac death, myocardial infarction, or TLR; 19.9% vs. 12.7%, P = 0.007) at 2 years. Among diabetic patients, SES reduced MACE by 47% (14.8% vs. 25.8%, HR = 0.52, P = 0.05) and TLR by 61% (7.4% vs. 17.2%, HR = 0.39, P = 0.03) compared with PES at 2 years.
Conclusion: Diabetic patients have worse prognosis than non-diabetic patients undergoing PCI with DES. Among the diabetic patient population of this trial, SES reduce repeat revascularization procedures and MACE more effectively than PES and to a similar degree as in non-diabetic patients.
Key Words: Coronary disease Stents Drugs Restenosis Diabetes
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Cook and P. Wenaweser Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis Circ Cardiovasc Interv, August 1, 2009; 2(4): 273 - 276. [Full Text] [PDF] |
||||
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF] |
||||
![]() |
O. Frobert, B. Lagerqvist, J. Carlsson, J. Lindback, U. Stenestrand, and S. K. James Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1660 - 1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al. A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus 2-Year Clinical Outcomes of the DES-DIABETES Trial. J. Am. Coll. Cardiol., March 3, 2009; 53(9): 812 - 813. [Full Text] [PDF] |
||||
![]() |
M. Chiu, D. T. Ko, P. C. Austin, E. A. Cohen, J. L. Velianou, R. Goeree, G. Blackhouse, and J. V. Tu Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 96 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Garg, S.-L. T. Normand, T. S. Silbaugh, R. E. Wolf, K. Zelevinsky, A. Lovett, M. R. Varma, Z. Zhou, and L. Mauri Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry Circulation, November 25, 2008; 118(22): 2277 - 2285. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial Eur. Heart J., November 2, 2008; 29(22): 2733 - 2741. [Abstract] [Full Text] [PDF] |
||||




